Lurbinectedin is a chemotherapy drug that is used to treat certain types of cancer. It works by preventing cancer cells from dividing and growing. Immunotherapy, on the other hand, is a type of cancer treatment that uses the body's immune system to fight cancer. It has been found to be effective in treating some types of cancer, but it is not without risks.

There is limited information available on the risks of combining lurbinectedin and immunotherapy. However, a clinical trial (NCT04358237) is currently underway to evaluate the safety and efficacy of combining lurbinectedin with pembrolizumab, an immunotherapy drug, in patients with small cell lung cancer (SCLC). The trial aims to determine the maximum tolerated dose of the combination therapy and assess its overall response rate and progression-free survival.

A study published in Targeted Oncology [3] evaluated the safety and efficacy of combining lurbinectedin with pembrolizumab in patients with relapsed SCLC. The study found that the combination therapy was well-tolerated and had a promising overall response rate. However, the study also noted that the combination therapy was associated with a higher incidence of adverse events, including fatigue, nausea, and anemia, compared to lurbinectedin alone.

In conclusion, while there is limited information available on the risks of combining lurbinectedin and immunotherapy, ongoing clinical trials and studies suggest that the combination therapy may be effective in treating certain types of cancer, but it may also be associated with a higher incidence of adverse events. It is important for patients to discuss the potential risks and benefits of combination therapy with their healthcare provider before starting treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.clinicaltrials.gov/ct2/show/NCT04358237
[3] https://www.targetedonc.com/view/second-line-lurbinectedin-plus-pembrolizumab-is-safe-and-effective-in-relapsed-sclc